Vanderbilt Institute For Chemical Biology

In the hunt for new therapeutics for cancer and infectious diseases, lasso peptides prove to be a catch. Their knot-like structures afford these molecules high stability and diverse biological activities, making them a promising avenue for new therapeutics. To better unleash their clinical potential, a team co-led by Doug Mitchell developed LassoESM, a new large language model for predicting lasso peptide properties. Read More

The Vanderbilt Institute of Chemical Biology held its annual Student Research Symposium on Aug. 1, drawing a record number of registrants and poster presenters. Organized by the Chemical Biology Association of Students, the event showcased cutting-edge research, interdisciplinary collaborations, and exceptional contributions from both trainees and faculty. Read More

A leading chemical biologist working on ribosomally synthesized and post-translationally modified peptides, Doug Mitchell has joined the School of Medicine Basic Sciences as the William Kelly Warren Sr. Professor of Biochemistry and director of the Vanderbilt Institute for Chemical Biology. He also has been named professor of chemistry. Read More

A leading chemical biologist working on ribosomally synthesized and post-translationally modified peptides, Doug Mitchell has joined the School of Medicine Basic Sciences as the William Kelly Warren Sr. Professor of Biochemistry and director of the Vanderbilt Institute for Chemical Biology. He also has been named professor of chemistry. Read More

Gary Sulikowski, Stevenson Professor of Chemistry, was named director of the Vanderbilt Institute for Chemical Biology in 2017. Since then, he has stewarded VICB’s growth and research operations. He shares how VICB has contributed to translational research, some of the research he's most excited about, and what makes Vanderbilt a rare place where powerful collaborative research can achieve its potential. Read More

By targeting a notoriously undruggable protein found in many cancers, the discovery of BI-0474 may pave the way for new cancer treatments. Shared on opnMe.com by Boehringer Ingelheim, this innovative molecule is available for global researchers to explore new research avenues. Read More

The World Health Organization ranks antimicrobial resistance as one of the top ten global health risks. Vanderbilt researchers led by Houra Merrikh identified the first anti-evolution compound that targets AMR during treatment of infections with antibiotics. Read More